At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 29 enrolled
Drug / intervention
LY3502970drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Multicenter, Parallel, Single-Dose, Open-Label, Single-Period Study of LY3502970 in Participants With Normal Hepatic Function and Participants With Mild, Moderate, or Severe Hepatic Impairment
In Brief
A Phase 1 clinical trial evaluating LY3502970 for Healthy and Hepatic Insufficiency. Completed, enrolled 29 participants across 4 sites.
Detailed Summary
The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to participants with normal liver function. The safety and tolerability of LY3502970 will also be evaluated. The study may last up to 6 weeks for each participant including the screening period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy, Hepatic Insufficiency
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
First PostedMay 2023
Enrollment StartJun 2023
Primary CompletionNov 2024
TodayJul 2026
First PostedMay 31, 2023
Enrollment StartJun 13, 2023
Primary CompletionNov 18, 2024
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 3.1 years ago
Interventions
LY3502970drug
Administered orally.